Carfilzomib, lenalidomide and dexamethasone in patients with heavily pretreated multiple myeloma: A phase 1 study in Japan. - Wikidata - wikimedia - TriplyDB

Carfilzomib, lenalidomide and dexamethasone in patients with heavily pretreated multiple myeloma: A phase 1 study in Japan.

Carfilzomib, lenalidomide and dexamethasone in patients with heavily pretreated multiple myeloma: A phase 1 study in Japan.

http://www.wikidata.org/entity/Q37735651

about

Weekly carfilzomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma: A phase 1 and PK/PD trial

P2860

Q58762364-2925FCBC-3F3B-46D1-AB0A-5F71CFDDDE16

P2860

Carfilzomib, lenalidomide and dexamethasone in patients with heavily pretreated multiple myeloma: A phase 1 study in Japan.

http://www.wikidata.org/entity/Q37735651

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 16 January 2017

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Carfilzomib, lenalidomide and ...... oma: A phase 1 study in Japan.

@en

Carfilzomib, lenalidomide and ...... oma: A phase 1 study in Japan.

@nl

type

label

Carfilzomib, lenalidomide and ...... oma: A phase 1 study in Japan.

@en

Carfilzomib, lenalidomide and ...... oma: A phase 1 study in Japan.

@nl

prefLabel

Carfilzomib, lenalidomide and ...... oma: A phase 1 study in Japan.

@en

Carfilzomib, lenalidomide and ...... oma: A phase 1 study in Japan.

@nl

P1433

Q37735651-BD901D45-B185-45A1-A61D-3F378BDC0459

P1476

Q37735651-198890E1-7549-415B-ABBC-A679A65DC260

P2093

Q37735651-108E2E63-44BF-4449-9A6F-F4B6D6E1BA83

Q37735651-14487137-D278-4BAA-9F9D-2B76459943FC

Q37735651-4FB642AA-E235-47CD-95E0-1EF8C45173FC

Q37735651-5E356DF4-7F36-4BF2-A96E-9DA433DABDD0

Q37735651-6A6F997F-2E5C-453C-97F8-113973B061E6

Q37735651-6BC00797-3A5A-4EF6-8155-198F11046867

Q37735651-6D91D151-8031-4247-A999-E26643A775FE

Q37735651-ACAAE1FD-8F08-4ED7-9E2D-3CA13FEAF4CB

Q37735651-ADD8F3E8-BC14-4726-AFDD-B093A6ED8E73

Q37735651-B2B9DCA5-A291-482B-812B-3FAA8D4F0AEC

P2860

Q37735651-00675EA6-A36E-4BC2-A33E-F97AB62EE62E

Q37735651-20C6254E-3E2A-4FF6-8FA7-2716844C25EC

Q37735651-50CD3996-D4F8-4F02-A2F1-284416934CA4

Q37735651-513D99D6-17A5-4E21-9E0F-3D511F4F0043

Q37735651-5F930F17-A9FE-4FDB-8114-88476D912111

Q37735651-7B501679-04A5-4884-86B0-98A914B5636B

Q37735651-7C2DF8FA-E321-4096-8331-D14C66882C7C

Q37735651-9DE0EA6C-873D-4A6B-8E99-C2111DFF4B0E

Q37735651-AC8BF684-BBB2-4806-8BEB-2CBB18D57F98

Q37735651-BCC0CAE9-4480-4AFC-81B4-316EF67126B0

P304

Q37735651-DEC8B8F7-D536-4F2C-A82D-32F70CBDF4BD

P31

Q37735651-11D269AE-B0C9-4EF4-92F1-5839B33F371D

P356

Q37735651-A9924EB7-14A9-42CB-B5F8-F710B6ED2211

P433

Q37735651-16368812-64C4-4674-BFE6-4310E32A82A5

P478

Q37735651-A69ECEC4-FEA2-4E13-8D2D-50CDC480202B

P577

Q37735651-39A622BD-050D-41DB-87D5-CACC2D0F4540

P698

Q37735651-FD5DCB76-2F06-48B0-AFCE-3DC074BCCF9B

P921

Q37735651-110C6FC8-266D-4E47-8C9F-BFE10C057C17

P932

Q37735651-6DA0F770-49AF-4426-8647-B3E2BA440158

P356

P1433

P1476

Carfilzomib, lenalidomide and ...... oma: A phase 1 study in Japan.

@en

P2093

Isamu Sugiura

http://www.w3.org/2001/XMLSchema#string

Kazutaka Sunami

http://www.w3.org/2001/XMLSchema#string

Kenji Ota

http://www.w3.org/2001/XMLSchema#string

Kenshi Suzuki

http://www.w3.org/2001/XMLSchema#string

Masaki Ri

http://www.w3.org/2001/XMLSchema#string

Naoki Takezako

http://www.w3.org/2001/XMLSchema#string

Shinsuke Iida

http://www.w3.org/2001/XMLSchema#string

Shuji Ozaki

http://www.w3.org/2001/XMLSchema#string

Tadao Ishida

http://www.w3.org/2001/XMLSchema#string

Takaaki Chou

http://www.w3.org/2001/XMLSchema#string

P2860

Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

International uniform response criteria for multiple myeloma.

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant.

Improved survival in multiple myeloma and the impact of novel therapies.

A phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myeloma

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.

Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and 'retreatment' approaches in the era of novel agents.

P304

461-468

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/CAS.13166

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

108

http://www.w3.org/2001/XMLSchema#string

P577

2017-01-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28092421

http://www.w3.org/2001/XMLSchema#string

P921

P932

5378280

http://www.w3.org/2001/XMLSchema#string